Treatment of Alzheimer’s diseases using donepezil nanoemulsion: an intranasal approach

Kaur, Atinderpal; Nigam, Kuldeep; Bhatnagar, Ishita; Sukhpal, Himanshu; Awasthy, Stuti; Shankar, Shivanika; Tyagi, Amit; Dang, Shweta

doi:10.1007/s13346-020-00754-z

Cited by 47 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Donepezil-loaded oil-in-water nanoemulsion (NE) is a new product formulated for intranasal administration. Studies by scintigraphy showed a maximum absorption of these NPs in the brain and could be an alternative for the use of donepezil hydrochloride in the treatment of AD [ 230 ].…”

Section: State-of-the-art Pharmaceutical Formulations and Nanomedicin...mentioning

confidence: 99%

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

Ailioaie

Litscher

2023

Pharmaceutics

View full text Add to dashboard Cite

Alzheimer’s disease (AD), as a neurodegenerative disorder, usually develops slowly but gradually worsens. It accounts for approximately 70% of dementia cases worldwide, and is recognized by WHO as a public health priority. Being a multifactorial disease, the origins of AD are not satisfactorily understood. Despite huge medical expenditures and attempts to discover new pharmaceuticals or nanomedicines in recent years, there is no cure for AD and not many successful treatments are available. The current review supports introspection on the latest scientific results from the specialized literature regarding the molecular and cellular mechanisms of brain photobiomodulation, as a complementary method with implications in AD. State-of-the-art pharmaceutical formulations, development of new nanoscale materials, bionanoformulations in current applications and perspectives in AD are highlighted. Another goal of this review was to discover and to speed transition to completely new paradigms for the multi-target management of AD, to facilitate brain remodeling through new therapeutic models and high-tech medical applications with light or lasers in the integrative nanomedicine of the future. In conclusion, new insights from this interdisciplinary approach, including the latest results from photobiomodulation (PBM) applied in human clinical trials, combined with the latest nanoscale drug delivery systems to easily overcome protective brain barriers, could open new avenues to rejuvenate our central nervous system, the most fascinating and complex organ. Picosecond transcranial laser stimulation could be successfully used to cross the blood-brain barrier together with the latest nanotechnologies, nanomedicines and drug delivery systems in AD therapy. Original, smart and targeted multifunctional solutions and new nanodrugs may soon be developed to treat AD.

show abstract

Section: State-of-the-art Pharmaceutical Formulations and Nanomedicin...mentioning

confidence: 99%

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

Ailioaie

Litscher

2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…By comprising gellan and konjac gums, the optimized nanostructured cubosomal by situ nasal gel dispersion and mucoadhesive, which substantially boosted transnasal penetration and strengthened accumulation inside the brain by contrast with free drug solution. Kaur et al develop the donepezil nano emulsion by labrasol, cetyl pyridinium chloride, and glycerol (Kaur, Nigam, Bhatnagar, et al, 2020). The pharmacokinetic studies of the technetium pertechnetate ( 99m Tc) labeled formulations when administered intranasally illustrated better retention of drug in the brain than the free drug solution and formulation administered orally and intravenously in Sprague-Dawley rats.…”

Section: Ache Inhibitors and Nmda Receptor Antagonistsmentioning

confidence: 99%

Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases

Wang

Gonzalez

Cordova

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Neurodegenerative diseases are posing pressing health issues due to the high prevalence among aging populations in the 21st century. They are evidenced by the progressive loss of neuronal function, often associated with neuronal necrosis and many related devastating complications. Nevertheless, effective therapeutical strategies to treat neurodegenerative diseases remain a tremendous challenge due to the multisystemic nature and limited drug delivery to the central nervous system. As a result, there is a pressing need to develop effective alternative therapeutics to manage the progression of neurodegenerative diseases. By utilizing the functional reconstructive materials and technologies with specific targeting ability at the nanoscale level, nanotechnology‐empowered medicines can transform the therapeutic paradigms of neurodegenerative diseases with minimal systemic side effects. This review outlines the current applications and progresses of the nanotechnology‐enabled drug delivery systems to enhance the therapeutic efficacy in treating neurodegenerative diseases.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

“…From these findings, the authors suggested that the formulation may be an attractive approach for nose-to-brain delivery of donepezil, providing advances in the AD treatment. 108 In another study, Kaur et al developed a nanoemulsion to improve the nose-to-brain delivery of memantine which had a particle size of ~11 nm, PDI of 0.080, and ZP of −19.6 mV. In vitro release studies demonstrated that the nanoemulsion-loaded memantine originated 80% of drug release in simulated nasal fluid, following a first-order kinetic model.…”

Section: Current Strategies To Improve the Treatment Of Alzheimer’s Diseasementioning

confidence: 99%

Improving Drug Delivery for Alzheimer’s Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels

Cunha¹,

Forbes²,

Lobo³

et al. 2021

IJN

View full text Add to dashboard Cite

Current treatments for Alzheimer’s disease (AD) attenuate the progression of symptoms and aim to improve the patient’s quality of life. Licensed medicines are mostly for oral administration and are limited by the difficulty in crossing the blood–brain barrier (BBB). Here in, the nasal route has been explored as an alternative pathway that allows drugs to be directly delivered to the brain via the nasal cavity. However, clearance mechanisms in the nasal cavity impair the delivery of drugs to the brain and limit their bioavailability. To optimize nose-to-brain delivery, formulations of lipid-based nanosystems, namely nanoemulsions and nanostructured lipid carriers (NLC), formulated in situ gelling hydrogels have been proposed as approaches for nose-to-brain delivery. These formulations possess characteristics that facilitate drug transport directly to the brain, minimizing side effects and maximizing therapeutic benefits. It has been recommended that the manufacture of these drug delivery systems follows the quality by design (QbD) approach based on nasal administration requirements. This review provides an insight into the current knowledge of the AD, highlighting the need for an effective drug delivery to the brain. Considering the mounting interest in the use of nanoemulsions and NLC for nose-to-brain delivery, a description of drug transport pathways in the nasal cavity and the application of these nanosystems and their in situ hydrogels through the intranasal route are presented. Relevant preclinical studies are summarised, and the future prospects for the use of lipid-based nanosystems in the treatment of AD are emphasized.

show abstract

Treatment of Alzheimer’s diseases using donepezil nanoemulsion: an intranasal approach

Cited by 47 publications

References 30 publications

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases

Improving Drug Delivery for Alzheimer’s Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels

Contact Info

Product

Resources

About